Clearmind Medicine Inc. Common Shares
CMNDClearmind Medicine Inc. is a biotechnology company focused on developing psychedelic-based treatments for mental health disorders. The company aims to leverage novel compounds and research to address conditions such as addiction, depression, and other psychiatric issues. Based in Canada, Clearmind collaborates with scientific and clinical partners to advance its innovative therapies.
Company News
Clearmind Medicine received a Nasdaq notice for not meeting minimum bid price requirements, with 180 days to regain compliance or risk potential delisting.
The substance use disorder market is expected to grow between 2025 and 2034, driven by greater awareness, the introduction of new therapies, and ongoing research and development efforts. The report covers the market assessment of Alcohol Use Disorder, Cocaine Use Disorder, Opioid Use Disorder, and Cannabis Use Disorder.
SciSparc and Clearmind Medicine have filed an international patent application for a novel treatment targeting anorexia, bulimia, and other eating disorders. The treatment combines 3-Methylmethcathinone (3-MMC) with SciSparc's Palmitoylethanolamide (PEA) to address the complex neurobiological and psychological factors associated with eating disor...
Clearmind Medicine has filed an international patent application for a novel treatment targeting anorexia, bulimia, and other eating disorders. The treatment combines 3-Methylmethcathinone (3-MMC) and Palmitoylethanolamide (PEA) to address the complex neurobiological and psychological factors associated with eating disorders.
Clearmind Medicine Inc. has been granted a patent by the Macau International Intellectual Property Office for its proprietary MEAI-based binge behavior regulator program. This patent further strengthens the company's global intellectual property portfolio, which now includes 31 granted patents across 18 patent families.
